Cells that line the blood vessels do not behave identically but instead exhibit varied responses to the same biochemical signals, British researchers report in Science.
Differences in microbiome composition can help to distinguish inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), Dutch and US researchers report.
Cancer specialist Cellestia Biotech AG has secured CHF20m through a Series A financing led by FC Capital, and PPF / Sotio, and ETP Ventures, Boston & Beijing.
Staten Biotechnology has signed a dyslipidaemia licence option deal worth US$430m with Novo Nordisk.
Paris-based Kurma Partners announced the first closing of its Kurma Biofund III, a life science fund set to raise €150m.
The European Parliament has voted to add €36.5bn to the budget of Horizon Europe (€94.1bn, in 2018 prices) proposed by the European Commission to foster research and innovation.
Cancer immunotherapies are often associated with severe cytokine release syndrome (CRS) that can be managed with IL-6R-blockers. US oncologists now report that an FDA-approved hypertension drug did the same job as Roche’s anti-IL-6R blocker tocolizumab.
In autumn, stakeholders across the globe pledged to take more action in the fight against antimicrobial resistance (AMR). Whereas from the push side new public and private initiatives appeared on the screen, discussion about which pull mechanism should be started first is in full swing. Meanwhile, small and medium-sized companies combine forces aiming to propel preclinical and early clinical R&D.
Immuncheckpoint specialist Oxford BioTherapeutics has licenced the right to develop five bispecific antibodies for combination therapies using Wuxi Biologics WuXiBody platform.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its Board of Directors has named Daniel ODay Chairman of the Board and Chief Executive Officer, effective March 1, 2019. Mr. ODay is currently the CEO of Roche Pharmaceuticals. He has held the position since 2012, and prior to that led Roche Diagnostics.